Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yang, Dae Yul | - |
dc.contributor.author | Seo, Won-Woo | - |
dc.contributor.author | Park, Rae Woong | - |
dc.contributor.author | Rhee, Sang Youl | - |
dc.contributor.author | Cha, Jae Myung | - |
dc.contributor.author | Hah, Yoon Soo | - |
dc.contributor.author | Jeong, Chang Won | - |
dc.contributor.author | Kim, Kyung-Jin | - |
dc.contributor.author | Yang, Hyeon-Jong | - |
dc.contributor.author | Kim, Do Kyung | - |
dc.contributor.author | Ha, Ji Yong | - |
dc.date.accessioned | 2024-06-12T01:31:55Z | - |
dc.date.available | 2024-06-12T01:31:55Z | - |
dc.date.issued | 2024-05 | - |
dc.identifier.issn | 2287-4208 | - |
dc.identifier.issn | 2287-4690 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26334 | - |
dc.description.abstract | Purpose: Finasteride and dutasteride are used to treat benign prostatic hyperplasia (BPH) and reduce the risk of developing prostate cancer. Finasteride blocks only the type 2 form of 5-alpha-reductase, whereas dutasteride blocks both type 1 and 2 forms of the enzyme. Previous studies suggest the possibility that dutasteride may be superior to finasteride in preventing prostate cancer. We directly compared the effects of finasteride and dutasteride on the risk of prostate cancer in patients with BPH using a pooled analysis of 15 real-world databases. Materials and Methods: We conducted a multicenter, cohort study of new-users of finasteride and dutasteride. We include patients who were prescribed 5 mg finasteride or dutasteride for the first time to treat BPH and had at least 180 days of prescription. We excluded patients with a history of prostate cancer or a prostate-specific antigen level >= 4 ng/mL before the study drug prescription. Cox regression analysis was performed to examine the hazard ratio (HR) for prostate cancer after propensity score (PS) matching. Results: A total of 8,284 patients of new-users of finasteride and 8,670 patients of new-users of dutasteride were included across the 15 databases. In the overall population, compared to dutasteride, finasteride was associated with a lower risk of prostate cancer in both on-treatment and intent-to-treat time-at-risk periods. After 1:1 PS matching, 4,897 patients using finasteride and 4,897 patients using dutasteride were enrolled in the present study. No significant differences were observed for risk of prostate cancer between finasteride and dutasteride both on-treatment (HR=0.66, 95% confidence interval [CI]: 0.44-1.00; p=0.051) and intent-to-treat time-at-risk periods (HR=0.87, 95% CI: 0.67-1.14; p=0.310). Conclusions: Using real-world databases, the present study demonstrated that dutasteride was not associated with a lower risk of prostate cancer than finasteride in patients with BPH. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN SOC SEXUAL MEDICINE & ANDROLOGY | - |
dc.title | Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.5534/wjmh.230327 | - |
dc.identifier.scopusid | 2-s2.0-85195055164 | - |
dc.identifier.wosid | 001229407200001 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF MENS HEALTH | - |
dc.citation.title | WORLD JOURNAL OF MENS HEALTH | - |
dc.type.docType | Article; Early Access | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalResearchArea | Health Care Sciences & Services | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Andrology | - |
dc.relation.journalWebOfScienceCategory | Health Care Sciences & Services | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | TYPE-1 | - |
dc.subject.keywordPlus | COMPARATOR | - |
dc.subject.keywordPlus | INHIBITORS | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | MEN | - |
dc.subject.keywordAuthor | Dutasteride | - |
dc.subject.keywordAuthor | Finasteride | - |
dc.subject.keywordAuthor | Prostatic hyperplasia | - |
dc.subject.keywordAuthor | Prostatic neoplasms | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.